For well-characterized AML phenotypes (including NPM1-mutant, CBF, and APL), follow-up testing is also recommended by bone marrow sampling every 3 months or peripheral blood every 4–6 weeks in the first 24 months after treatment completion [10]. This evidence concerns the gene CEBPZ and acute promyelocytic leukemia.